Editorial Commentary: Considerations of Favipiravir as a Medical Countermeasure in Future Randomized Controlled Trials Against Ebola Virus Disease

Editorial Commentary: Considerations of Favipiravir as a Medical Countermeasure in Future Randomized Controlled Trials Against Ebola Virus Disease

Elemento

Click for External Resource*

https://www.ncbi.nlm.nih.gov/pubmed/27553374

Click to read full article*

https://academic.oup.com/cid/article/63/10/1295/2450073

The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.

Files for Download

Editorial Commentary: Considerations of Favipiravir as a Medical Countermeasure in Future Randomized Controlled Trials Against Ebola Virus Disease

http://repository.netecweb.org/pdfs/ciw575.pdf

Item Type

Publicación

Terms of Use

By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.

Visor de documentos

Share this page:

Facebook Twitter e-mail

Was this resource helpful?

Título

Editorial Commentary: Considerations of Favipiravir as a Medical Countermeasure in Future Randomized Controlled Trials Against Ebola Virus Disease

Materia

Research

Descripción

Since the discovery of Ebola virus in the Democratic Republic of Congo in 1976, outbreaks of EVD had been mainly confined to rural areas (http://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html)...

Autor

Kraft, C. S.

Fecha

2016-11-15

Tipo

Publication

Citación

Kraft, C. S. (2016). "Editorial Commentary: Considerations of Favipiravir as a Medical Countermeasure in Future Randomized Controlled Trials Against Ebola Virus Disease." Clin Infect Dis 63(10): 1295-1296.